New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
10:02 EDTSTJ, JNJ, COF, BDX, GLUU, LULU, PRGO, UNH, PLL, CVD, BRO, AJG, LMT, MGM, ABV, WDAY, STI, LOGI, CLR, BDN, SHW, BBT, YUM, VAROn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Arthur J. Gallagher (AJG) upgraded to Overweight from Equal Weight at Barclays... Becton Dickinson (BDX) upgraded to Neutral from Underperform at BofA/Merrill... Brandywine Realty (BDN) upgraded to Outperform from Market Perform at Raymond James... Brown & Brown (BRO) upgraded to Overweight from Equal Weight at Barclays... Capital One (COF) upgraded to Conviction Buy from Buy at Goldman... Continental Resources (CLR) upgraded to Buy from Neutral at BofA/Merrill... Covance (CVD) upgraded to Buy from Hold at Jefferies... Johnson & Johnson (JNJ) upgraded to Outperform from Sector Perform at RBC Capital... Logitech (LOGI) upgraded to Equal Weight from Underweight at Barclays... Pall Corp. (PLL) upgraded to Buy from Neutral at BofA/Merrill... St. Jude Medical (STJ) upgraded to Sector Perform from Underperform at RBC Capital... SunTrust (STI) upgraded to Outperform from Market Perform at BMO Capital... UnitedHealth (UNH) upgraded to Buy from Hold at Deutsche Bank... Varian Medical (VAR) upgraded to Neutral from Sell at Citigroup... Workday (WDAY) upgraded to Buy from Neutral at UBS... Yum! Brands (YUM) upgraded to Top Pick from Outperform at RBC Capital... Perrigo (PRGO) upgraded to Buy from Neutral at BofA/Merrill... AmBev (ABV) upgraded to Overweight from Equal Weight at Morgan Stanley... lululemon (LULU) upgraded to Buy from Neutral at DA Davidson... MGM Resorts (MGM) upgraded to Overweight from Equal Weight at Morgan Stanley... Glu Mobile (GLUU) upgraded to Buy from Hold at Craig-Hallum... BB&T (BBT) upgraded to Overweight from Neutral at JPMorgan... Sherwin-Williams (SHW) upgraded to Buy from Hold at KeyBanc... Lockheed Martin (LMT) upgraded to Buy from Neutral at BofA/Merrill.
News For AJG;BDX;BDN;BRO;COF;CLR;CVD;JNJ;LOGI;PLL;STJ;STI;UNH;VAR;WDAY;PRGO;YUM;ABV;LULU;BBT;MGM;GLUU;SHW;LMT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
March 18, 2015
05:39 EDTSTJSt. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.
March 17, 2015
16:26 EDTMGMOn The Fly: Closing Wrap
Subscribe for More Information
16:00 EDTMGMOptions Update; March 17, 2015
iPath S&P 500 VIX Short-Term Futures down 11c to 27.30. Option volume leaders: AAPL RIG MGM HTZ TWTR TSLA CY KO NFLX C according to Track Data.
14:41 EDTLMTLockheed Martin nearing F-16 upgrade deal with Singapore, Defense News says
Subscribe for More Information
10:42 EDTBBTBB&T remains an underappreciated story, says BofA/Merrill
BofA/Merrill reiterated its Buy rating and $44 price target on BB&T and said it remains an underappreciated and under-owned. The firm notes BB&T is using excess capital and currency strength to return capital to shareholders and pursue accretive deals. BofA/Merrill thinks the Susquehanna deal could prove more beneficial than the market perceives and its excess liquidity position makes it more rate sensitive versus peers. Shares are Buy rated with a $44 price target.
10:11 EDTMGMMGM Resorts trades sharply higher as activist suggests REIT conversion
Land and Buildings laid out a proposal to unlock value in the shares by pursuing a REIT conversion at MGM Resorts. At the current price of $21.36, the stock is up over 8.6%. Resistance initially is at the session high at $21.50, and then at $21.76. Support is at the 50-day moving average at $20.73.
10:00 EDTWDAYOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aimco (AIV) initiated with an Outperform at RW Baird... Alnylam (ALNY) initiated with a Buy at Janney Capital... American Campus (ACC) initiated with a Neutral at RW Baird... AvalonBay (AVB) initiated with a Neutral at RW Baird... BE Aerospace (BEAV) initiated with a Buy at CRT Capital... BlackRock (BLK) initiated with a Buy at Argus... Camden Property (CPT) initiated with an Outperform at RW Baird... CarMax (KMX) initiated with a Buy at Evercore ISI... Central Pacific (CPF) initiated with a Neutral at Macquarie... Cognex (CGNX) initiated with a Buy at Northcoast... Education Realty (EDR) initiated with a Neutral at RW Baird... EnerSys (ENS) initiated with an Overweight at Stephens... Equity Lifestyle (ELS) initiated with an Outperform at RW Baird... Equity Residential (EQR) initiated with a Neutral at RW Baird... Essex Property Trust (ESS) initiated with a Neutral at RW Baird... Facebook (FB) initiated with a Buy at Brean Capital... Intercept (ICPT) initiated with a Hold at MLV & Co.... Isis Pharmaceuticals (ISIS) initiated with a Neutral at Janney Capital... LinkedIn (LNKD) initiated with a Sell at Brean Capital... Mid-America Apartment (MAA) initiated with an Outperform at RW Baird... NetSuite (N) initiated with a Hold at Brean Capital... Paycom (PAYC) initiated with a Buy at Brean Capital... Platform Specialty Products (PAH) initiated with a Buy at UBS... Post Properties (PPS) initiated with a Neutral at RW Baird... Salesforce.com (CRM) initiated with a Hold at Brean Capital... ServiceNow (NOW) initiated with a Buy at Brean Capital... Snap-On (SNA) initiated with a Buy at Northcoast... Sun Communities (SUI) initiated with a Neutral at RW Baird... Twitter (TWTR) initiated with a Buy at Brean Capital... UDR, Inc. (UDR) initiated with an Outperform at RW Baird... Workday (WDAY) initiated with a Hold at Brean Capital... Xplore Technologies (XPLR) initiated with a Buy at Roth Capital... Yahoo (YHOO) initiated with a Hold at Argus.
09:25 EDTGLUUOn The Fly: Pre-market Movers
Subscribe for More Information
09:25 EDTMGMLand and Buildings proposes REIT conversion for MGM Resorts
Subscribe for More Information
09:03 EDTBDXBecton Dickinson completes acquisition of CareFusion
Becton Dickinson (BDX) announced that it completed its acquisition of CareFusion (CFN) pursuant to the terms of its previously announced Agreement and Plan of Merger, dated October 5, 2014. Pursuant to the terms of the Merger Agreement, upon completion of the acquisition, CareFusion became a wholly-owned subsidiary of BD. Excluding transaction-related expenses relating to the closing, BD expects the acquisition to have an immaterial impact on the company's results of operations in the second fiscal quarter, which ends on March 31, 2015.
08:41 EDTGLUUGlu Mobile to partner with Kendall, Kylie Jenner on new mobile game
Glu Mobile announced that the company will partner with Kendall and Kylie Jenner on the development of a new mobile game. Featuring the voices, likenesses, and creative influences of Kendall and Kylie, the game will allow players to interact with the sisters as friends and mentors as they work to realize their creative and career aspirations. Glu expects to launch the game worldwide in late 2015 on iOS and Android. Glu will provide additional details on the game's development and Kendall and Kylie's involvement at a later date. Shares of Glu Mobile, the maker of "Kim Kardashian: Hollywood," are up about 7% in pre-market trading to $5.15.
08:08 EDTVARVarian Medical to create operating entity in Algeria
Subscribe for More Information
07:18 EDTLMTSatellite & Access Intelligence to hold a exhibition
Subscribe for More Information
05:35 EDTJNJJohnson & Johnson to invest $10M in UK government fund to fight dementia
Subscribe for More Information
March 16, 2015
16:17 EDTWDAYWorkday initiated with a Hold at Brean Capital
Subscribe for More Information
15:04 EDTJNJPharmacyclics says committee recommends unblinding after primary endpoint met
Subscribe for More Information
13:16 EDTSTJAnalysts upbeat on results of Edwards' Sapien 3 data
The shares of Edwards Lifesciences (EW) are rising after the company released data on its Sapien 3 transcathter aortic valve over the weekend. In notes to investors today, a number of analysts were upbeat on the data. BACKGROUND: Edwards yesterday announced that high- and intermediate-risk patients treated with Sapien 3 demonstrated lower mortality rates than patients treated with previous transcathter aortic valves, or TAVR, made by the company. The patients also had excellent clinical outcomes in the other primary endpoints of stroke and paravalvular regurgitation, the company stated. Meanwhile, a five year study of patients treated with the first generation SAPIEN device showed that the patients had equivalent outcomes to traditional open-heart surgery, and no structural valve deterioration requiring intervention, the company stated. ANALYST REACTION: Edwards' Sapien 3 data was impressive, as the device showed one of the lowest stroke and mortality rates of any major TAVR study so far, Bernstein analyst Derrick Sung wrote in a note to investors earlier today. Data presented by Edwards and other companies at the American College of Cardiology, or ACC, conference this weekend caused investors and the medical community to become more optimistic about the potential for TAVR devices to replace surgical valves, Sung stated. The analyst wrote that he continues to believe that investors are underestimating the potential size of the TAVR market. Also upbeat on Edwards' data was Wells Fargo, which wrote that the data exceeded high expectations and could pressure the FDA to approve Sapien 3 for intermediate risk patients earlier than Edwards' guidance of late 2016. WHAT'S NOTABLE: Analysts were also upbeat on data reported by other companies at the ACC conference. Medtronic's (MDT) data suggested that its CoreValve Evolut-R product may be as effective as Edwards' Sapien 3, Bernstein's Sung stated. The FDA appears to have allowed Boston Scientific's (BSX) left atrial appendage closure, Watchman, to be provided to more patients than expected, research firm Stifel believes. Meanwhile, St. Jude's (STJ) CardioMEMS device yielded "impressive" mortality data, the firm added. Stifel kept Buy ratings on both Medtronic and St. Jude. PRICE ACTION: In early afternoon trading, Edwards Lifesciences climbed 9% to $147.64, Boston Scientific advanced 4% to $17.27, St. Jude added 2% to $67.55, and Medtronic rose 1.3% to $77.50.
08:25 EDTCOFCapital One reports February net charge-off rate 3.47% vs. 3.57% last month
Reports February 30+ day performing delinquency rate 3.17% vs. 3.31% last month.
08:05 EDTSTJSt. Jude Medical data 'impressive,' says BMO Capital
Subscribe for More Information
March 15, 2015
12:47 EDTSTJSt. Jude Medical announces new data analysis from CHAMPION trial
St. Jude Medical announced a new data analysis from the CHAMPION trial showing that heart failure, HF, patients with reduced ejection fraction on optimal doses of guideline directed medical therapy, GDMT, managed by pulmonary artery, PA, pressure monitoring with the CardioMEMS HF System had a 57% reduction in mortality and a 43% reduction in HF hospitalizations compared with patients on GDMT managed by the standard of care, SOC. These data show a strong improvement for patients managed by optimal GDMT and the CardioMEMS HF System in both mortality and hospitalizations over currently defined best practices.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use